- Home
- ATYR vs NTRB Comparison
ATYR vs NTRB Comparison
Compare ATYR & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- NTRB
- Stock Information
- Founded
- ATYR 2005
- NTRB 2016
- Country
- ATYR United States
- NTRB United States
- Employees
- ATYR N/A
- NTRB N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- NTRB Industrial Specialties
- Sector
- ATYR Health Care
- NTRB Health Care
- Exchange
- ATYR Nasdaq
- NTRB Nasdaq
- Market Cap
- ATYR 105.8M
- NTRB 87.2M
- IPO Year
- ATYR 2015
- NTRB N/A
- Fundamental
- Price
- ATYR $0.93
- NTRB $7.99
- Analyst Decision
- ATYR Buy
- NTRB Buy
- Analyst Count
- ATYR 6
- NTRB 1
- Target Price
- ATYR $8.88
- NTRB $13.00
- AVG Volume (30 Days)
- ATYR 23.5M
- NTRB 33.4K
- Earning Date
- ATYR 11-06-2025
- NTRB 09-09-2025
- Dividend Yield
- ATYR N/A
- NTRB N/A
- EPS Growth
- ATYR N/A
- NTRB N/A
- EPS
- ATYR N/A
- NTRB N/A
- Revenue
- ATYR N/A
- NTRB $2,578,059.00
- Revenue This Year
- ATYR $420.85
- NTRB $560.75
- Revenue Next Year
- ATYR $1,919.44
- NTRB $588.39
- P/E Ratio
- ATYR N/A
- NTRB N/A
- Revenue Growth
- ATYR N/A
- NTRB 42.92
- 52 Week Low
- ATYR $0.68
- NTRB $2.98
- 52 Week High
- ATYR $7.29
- NTRB $9.42
- Technical
- Relative Strength Index (RSI)
- ATYR 27.94
- NTRB 62.60
- Support Level
- ATYR $0.68
- NTRB $7.30
- Resistance Level
- ATYR $0.86
- NTRB $8.63
- Average True Range (ATR)
- ATYR 0.08
- NTRB 0.41
- MACD
- ATYR 0.13
- NTRB 0.12
- Stochastic Oscillator
- ATYR 69.00
- NTRB 72.69
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.